Science 37 Introduces Virtual Site Model to Rescue Slow Enrolling Clinical Trials
May 12 2022 - 4:01PM
Science 37 Holdings, Inc. (Nasdaq: SNCE), the Agile Clinical Trial
Operating System™, today introduced a rapid-deployment virtual site
model for slow enrolling clinical trials to access patients beyond
the existing site-based network.
Globally, 80% of clinical trials experience delays because of
slow patient enrollment, representing an estimated 16,000 active
trials. A primary driver for this poor enrollment is the limited
number of traditional clinical trial investigators and the
geographic limitations of those investigative sites to recruit
patients.
The Science 37 virtual site model to rescue slow enrolling
studies, called Metasite Rescue™, enables sponsors to reach nearly
any patient, anywhere, through a virtual site network that is not
limited by geography. It enables patients to participate in
clinical research from the comfort of their own home and to
interface with remote coordinators, telemedicine investigators,
community providers, mobile nurses and connected devices. Workflow
orchestration is enabled by the Company’s recently released next
generation technology platform that can be deployed in just four
weeks for such studies.
“The most common action taken in an attempt to rescue a
vulnerable trial is to open more physical sites, which is often
throwing good money after bad,” said Darcy Forman, Chief Delivery
Officer of Science 37. “Sponsors alternatively will hire a patient
recruitment firm to find patients directly and refer them to
existing sites that may be several hours away. With Science 37’s
Metasite Rescue solution, not only can we find the patients, but we
can also enroll them almost immediately wherever they are, and
manage the complete study conduct for that patient, in an expedited
manner to ultimately get the trial back on schedule.”
To learn more about the Science 37 Metasite™ and how it has
enabled up to 21x faster enrollment to subtract months off clinical
trial timelines, visit www.science37.com/metasite.
About Science 37Science 37 Holdings, Inc.’s (Nasdaq: SNCE)
mission is to enable universal access to clinical research—making
it easier for patients and providers to participate from anywhere
and helping to accelerate the development of treatments that impact
patient lives. As a pioneer of decentralized clinical trials, the
Science 37 l Operating System (OS) supports today’s more agile
clinical research designs with its full-stack, end-to-end
technology platform and centralized networks of patient
communities, telemedicine investigators, mobile nurses, remote
coordinators, provider communities, and data and devices.
Configurable to enable almost any study type, the Science 37 OS
enables up to 21x faster enrollment, 28% better retention, and 3x
more diverse patient population with industry-leading workflow
orchestration, evidence generation, and data harmonization. For
more information, visit https://www.science37.com.
MEDIA INQUIRIES:Drew BustosScience 37pr@science37.com
INVESTOR RELATIONS:Caroline PaulScience 37 //
GilmartinInvestors@science37.com
Science 37 (NASDAQ:SNCE)
Historical Stock Chart
From Jun 2024 to Jul 2024
Science 37 (NASDAQ:SNCE)
Historical Stock Chart
From Jul 2023 to Jul 2024